Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. Journal of Clinical Oncology, 40, no. 17_suppl (June10, 2022) LBA3-LBA3
2.
Enhertu Benefit in HER2-Low Breast Cancer Wows at ASCO; Signals Shifting Therapy, Dx Paradigms; Precision Oncology News; June6, 2022
3.
ASCO: HER2 diagnostics need a revolution as AstraZeneca, Daiichi's Enhertu looks to redefine breast cancer; Fierce Biotech; June6, 2022.
4.
Strata PATH™ (Precision Indications for Approved Therapies); ClinicalTrials.gov Identifier: NCT05097599
